AMD after cataract surgery unclear

Article

The answer may be found in the masking effects of catract upon pre-existing disease

The association between cataract surgery and progression of age-related macular degeneration (AMD) still is unclear, said Dr Neil M. Bressler.

In light of this uncertainty, ophthalmologists can consider cataract surgery even in patients with AMD if the cataract affects vision and the patient's quality of life, Dr Bressler added.

Globally, cataracts are one of the leading causes of blindness, and according to the World Health Organization (WHO) "age-related cataract are responsible for 48% of world blindness." Additionally, WHO reports that in its 2010 estimates AMD is in the top three causes of blindness.1

Yet, there are questions as to the association between cataract surgery and the progression of AMD. According to Dr Bressler, clinical evidence shows no increase in risk for progression to advanced AMD after cataract surgery.

"If you think the cataract is visually significant to a patient, you should consider removing the cataract," he said. "There is no clear evidence that AMD eyes are at clinically important greater risk for progression to advanced AMD following cataract surgery."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.